Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1991 2
1992 2
1993 1
1994 1
1995 2
1996 2
1997 5
1998 1
2000 1
2001 1
2002 5
2003 2
2004 2
2006 2
2008 1
2009 2
2010 2
2011 3
2012 4
2013 6
2014 4
2015 1
2016 4
2017 2
2018 2
2019 5
2020 7
2021 16
2022 11
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
A cross-population atlas of genetic associations for 220 human phenotypes.
Sakaue S, Kanai M, Tanigawa Y, Karjalainen J, Kurki M, Koshiba S, Narita A, Konuma T, Yamamoto K, Akiyama M, Ishigaki K, Suzuki A, Suzuki K, Obara W, Yamaji K, Takahashi K, Asai S, Takahashi Y, Suzuki T, Shinozaki N, Yamaguchi H, Minami S, Murayama S, Yoshimori K, Nagayama S, Obata D, Higashiyama M, Masumoto A, Koretsune Y; FinnGen; Ito K, Terao C, Yamauchi T, Komuro I, Kadowaki T, Tamiya G, Yamamoto M, Nakamura Y, Kubo M, Murakami Y, Yamamoto K, Kamatani Y, Palotie A, Rivas MA, Daly MJ, Matsuda K, Okada Y. Sakaue S, et al. Among authors: yoshimori k. Nat Genet. 2021 Oct;53(10):1415-1424. doi: 10.1038/s41588-021-00931-x. Epub 2021 Sep 30. Nat Genet. 2021. PMID: 34594039
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Maemondo M, et al. Among authors: yoshimori k. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. N Engl J Med. 2010. PMID: 20573926 Free article. Clinical Trial.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: yoshimori k. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Katakami N, et al. Among authors: yoshimori k. Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. Cancer. 2018. PMID: 29205286 Free PMC article. Clinical Trial.
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Saito H, et al. Among authors: yoshimori k. Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8. Lancet Oncol. 2019. PMID: 30975627 Clinical Trial.
Anti-Mi-2 antibody-positive lung cancer-associated polymyositis.
Shimoda M, Tanaka Y, Taniguchi A, Morimoto K, Yoshimori K, Ohta K. Shimoda M, et al. Among authors: yoshimori k. Int Cancer Conf J. 2023 Mar 14;12(3):173-176. doi: 10.1007/s13691-023-00601-1. eCollection 2023 Jul. Int Cancer Conf J. 2023. PMID: 37251005 Free PMC article.
Characteristics of "chūnibyō" identified by a questionnaire.
Shimoda M, Morimoto K, Tanaka Y, Yoshimori K, Ohta K. Shimoda M, et al. Among authors: yoshimori k. PLoS One. 2021 Nov 24;16(11):e0260375. doi: 10.1371/journal.pone.0260375. eCollection 2021. PLoS One. 2021. PMID: 34818343 Free PMC article.
Analysis of risk factors for the development of a post-bronchoscopy respiratory infection in lung cancer patients.
Shimoda M, Yamana K, Yano R, Saitou M, Fujiwara K, Furuuchi K, Osawa T, Uesugi F, Arakawa K, Morimoto K, Tanaka Y, Kokutou H, Okumura M, Uchiyama T, Ohta K, Yoshimori K. Shimoda M, et al. Among authors: yoshimori k. J Infect Chemother. 2021 Feb;27(2):237-242. doi: 10.1016/j.jiac.2020.09.029. Epub 2020 Oct 12. J Infect Chemother. 2021. PMID: 33060045 Review.
Interrelational changes in the epidemiology and clinical features of nontuberculous mycobacterial pulmonary disease and tuberculosis in a referral hospital in Japan.
Furuuchi K, Morimoto K, Yoshiyama T, Tanaka Y, Fujiwara K, Okumura M, Izumi K, Shiraishi Y, Mitarai S, Ogata H, Kurashima A, Yoshimori K, Ohta K, Goto H, Sasaki Y. Furuuchi K, et al. Among authors: yoshimori k. Respir Med. 2019 Jun;152:74-80. doi: 10.1016/j.rmed.2019.05.001. Epub 2019 May 8. Respir Med. 2019. PMID: 31128614 Free article. Review.
103 results